271 related articles for article (PubMed ID: 36636157)
1. Reflections on the state of diabetes research and prospects for treatment.
Accili D; Du W; Kitamoto T; Kuo T; McKimpson W; Miyachi Y; Mukhanova M; Son J; Wang L; Watanabe H
Diabetol Int; 2023 Jan; 14(1):21-31. PubMed ID: 36636157
[TBL] [Abstract][Full Text] [Related]
2. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Generation of β-Cells from Induced Pluripotent Stem Cells as a Potential Cure for Diabetes Mellitus.
Agrawal A; Narayan G; Gogoi R; Thummer RP
Adv Exp Med Biol; 2021; 1347():1-27. PubMed ID: 34426962
[TBL] [Abstract][Full Text] [Related]
4. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification.
Chen H; Guo J; Cai Y; Zhang C; Wei F; Sun H; Cheng C; Liu W; He Z
J Ethnopharmacol; 2024 Mar; 321():117481. PubMed ID: 38007164
[TBL] [Abstract][Full Text] [Related]
6. An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation.
Casteels T; Zhang Y; Frogne T; Sturtzel C; Lardeau CH; Sen I; Liu X; Hong S; Pauler FM; Penz T; Brandstetter M; Barbieux C; Berishvili E; Heuser T; Bock C; Riedel CG; Meyer D; Distel M; Hecksher-Sørensen J; Li J; Kubicek S
Mol Metab; 2021 Dec; 54():101329. PubMed ID: 34454092
[TBL] [Abstract][Full Text] [Related]
7. Glucagon receptor blockage inhibits β-cell dedifferentiation through FoxO1.
Wang K; Cui X; Li F; Xia L; Wei T; Liu J; Fu W; Yang J; Hong T; Wei R
Am J Physiol Endocrinol Metab; 2023 Jan; 324(1):E97-E113. PubMed ID: 36383639
[TBL] [Abstract][Full Text] [Related]
8. A Brief Review of the Mechanisms of β-Cell Dedifferentiation in Type 2 Diabetes.
Khin PP; Lee JH; Jun HS
Nutrients; 2021 May; 13(5):. PubMed ID: 34068827
[TBL] [Abstract][Full Text] [Related]
9. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
Ozawa H; Murai Y; Ozawa T
Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
[TBL] [Abstract][Full Text] [Related]
10. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
11. The new biology of diabetes.
Pajvani UB; Accili D
Diabetologia; 2015 Nov; 58(11):2459-68. PubMed ID: 26248647
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Veelen A; Erazo-Tapia E; Oscarsson J; Schrauwen P
Mol Metab; 2021 Apr; 46():101158. PubMed ID: 33387681
[TBL] [Abstract][Full Text] [Related]
13. Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling.
Chen H; Zhou W; Ruan Y; Yang L; Xu N; Chen R; Yang R; Sun J; Zhang Z
Mol Med; 2018 Aug; 24(1):43. PubMed ID: 30134927
[TBL] [Abstract][Full Text] [Related]
14. Noradrenergic fibers are associated with beta-cell dedifferentiation and impaired beta-cell function in humans.
Cinti F; Mezza T; Severi I; Suleiman M; Cefalo CMA; Sorice GP; Moffa S; Impronta F; Quero G; Alfieri S; Mari A; Pontecorvi A; Marselli L; Cinti S; Marchetti P; Giaccari A
Metabolism; 2021 Jan; 114():154414. PubMed ID: 33129839
[TBL] [Abstract][Full Text] [Related]
15. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications.
Wysham C; Shubrook J
Postgrad Med; 2020 Nov; 132(8):676-686. PubMed ID: 32543261
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional control of pancreatic β-cell identity and plasticity during the pathogenesis of type 2 diabetes.
Zhang Z; Gao Y; Meng ZX
J Genet Genomics; 2022 Apr; 49(4):316-328. PubMed ID: 35292418
[TBL] [Abstract][Full Text] [Related]
17. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.
Haddad D; Dsouza VS; Al-Mulla F; Al Madhoun A
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203742
[TBL] [Abstract][Full Text] [Related]
18. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications.
Bullock WH; Magnuson SR; Choi S; Gunn DE; Rudolph J
Curr Top Med Chem; 2002 Sep; 2(9):915-38. PubMed ID: 12171564
[TBL] [Abstract][Full Text] [Related]
19. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
Palmer JP; Fleming GA; Greenbaum CJ; Herold KC; Jansa LD; Kolb H; Lachin JM; Polonsky KS; Pozzilli P; Skyler JS; Steffes MW
Diabetes; 2004 Jan; 53(1):250-64. PubMed ID: 14693724
[TBL] [Abstract][Full Text] [Related]
20. The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients.
Chon S; Oh S; Kim SW; Kim JW; Kim YS; Woo JT
Korean J Intern Med; 2010 Sep; 25(3):273-81. PubMed ID: 20830224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
